Methylphenidate Viatris (Methylphenidate Hydrochloride)

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness, providing therapeutic benefit in specific disorders.

• Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in children, adolescents and adults.
• Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness in affected individuals.

• Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters, leading to increased synaptic concentrations of these catecholamines. The heightened neurotransmitter activity enhances neuronal firing in brain regions that regulate attention, impulse control, and arousal, thereby producing its therapeutic effects in ADHD and narcolepsy.

Methylphenidate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Insomnia: difficulty falling or staying asleep.
• Decreased appetite: reduced desire for food, potentially affecting weight.
• Headache: mild to moderate pain in the head.
• Irritability: heightened emotional sensitivity or mood swings.

Serious or Rare Side Effects

• Cardiovascular events: chest pain, hypertension, or arrhythmia.
• Psychosis: hallucinations or delusional thinking.
• Severe allergic reaction: rash, swelling, or difficulty breathing.

When prescribing methylphenidate, clinicians should consider several safety precautions to minimize risk.

• Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy.
• Growth monitoring: regularly assess height and weight in pediatric patients.
• Psychiatric evaluation: screen for history of psychosis, mania or severe anxiety.
• Drug abuse potential: avoid use in individuals with known substance misuse.
• Store at room temperature: keep in original container, protect from moisture and heat.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Tricyclic antidepressants: may increase cardiovascular side effects.
• Antipsychotics: can diminish stimulant effect.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin levels.

• CYP2D6 inhibitors (e.g., fluoxetine): can raise methylphenidate plasma concentrations.
• Alcohol: may exacerbate central nervous system stimulation.